Results 281 to 290 of about 1,442,988 (353)

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection. [PDF]

Blood Cancer J
Yee AJ.
europepmc   +1 more source

Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report. [PDF]

Front Immunol
Bernardi C, Beauverd Y, Tran TA, Maulini M, Mappoura M, Morin S, Simonetta F, Cairoli A, Auner HW, Samii K, Chalandon Y, de Ramon Ortiz C.   +11 more
europepmc   +1 more source

T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment. [PDF]

Blood Cancer Discov
van de Donk NWCJ, Rasche L, Sidana S, Zweegman S, Garfall AL.   +4 more
europepmc   +1 more source

Clinical Pharmacology of Cytokine Release Syndrome with T-Cell-Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies. [PDF]

Clin Cancer Res
Radtke KK, Bender BC, Li Z, Turner DC, Roy S, Belousov A, Li CC.   +6 more
europepmc   +1 more source

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. [PDF]

Blood Cancer J
Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TAW, Fenk R, Müller F, Tovar N, Oliver-Cáldes A, Rathje K, Davis JA, Fandrei D, Vucinic V, Kharboutli S, Baermann BN, Ayuk F, Platzbecker U, Albici AM, Schub N, Schmitz F, Shune L, Khouri J, Anwer F, Raza S, McGuirk J, Mahmoudjafari Z, Green K, Khandanpour C, Teichert M, Jeker B, Hoffmann M, Kröger N, von Tresckow B, de Larrea CF, Pabst T, Abdallah AO, Gagelmann N.   +37 more
europepmc   +1 more source

Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma. [PDF]

Haematologica
Melody M, Gordon LI.
europepmc   +1 more source

Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. [PDF]

Blood Adv
Reynolds GK, Maclean M, Cliff ERS, Teh BW, Thursky KA, Slavin MA, Anderson MA, Hawkes EA.   +7 more
europepmc   +1 more source

IGLV3-21^R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia

Fischer C, Stücheli S, Chen S, Nimmerfroh J, Schultheiß C, Widmer C, Heim D, Kasenda B, Passweg J, Kobold S, Egli L, Coianiz N, Chijioke O, Chiorazzi N, Follo M, Läubli H, Peipp M, Binder M.   +17 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bispecific antibodies in oncology

Nature Reviews Drug Discovery, 2022
A. Esfandiari, Sorcha A. Cassidy, Rachel M. Webster   +2 more
semanticscholar   +3 more sources